JP2022518150A5 - - Google Patents
Info
- Publication number
- JP2022518150A5 JP2022518150A5 JP2021539400A JP2021539400A JP2022518150A5 JP 2022518150 A5 JP2022518150 A5 JP 2022518150A5 JP 2021539400 A JP2021539400 A JP 2021539400A JP 2021539400 A JP2021539400 A JP 2021539400A JP 2022518150 A5 JP2022518150 A5 JP 2022518150A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- cancer
- antibody
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061674A JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789462P | 2019-01-07 | 2019-01-07 | |
| US62/789,462 | 2019-01-07 | ||
| US201962845829P | 2019-05-09 | 2019-05-09 | |
| US62/845,829 | 2019-05-09 | ||
| PCT/US2020/012637 WO2020146432A1 (en) | 2019-01-07 | 2020-01-07 | Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061674A Division JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518150A JP2022518150A (ja) | 2022-03-14 |
| JP2022518150A5 true JP2022518150A5 (enExample) | 2023-01-19 |
Family
ID=71520485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539400A Pending JP2022518150A (ja) | 2019-01-07 | 2020-01-07 | 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験 |
| JP2025061674A Pending JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061674A Pending JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220062339A1 (enExample) |
| EP (1) | EP3908296A4 (enExample) |
| JP (2) | JP2022518150A (enExample) |
| CN (1) | CN113490504A (enExample) |
| AU (1) | AU2020206117A1 (enExample) |
| CA (1) | CA3125751A1 (enExample) |
| WO (1) | WO2020146432A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022040088A2 (en) * | 2020-08-21 | 2022-02-24 | Synthekine, Inc. | Cd45 binding molecules and methods of use |
| GB202015226D0 (en) | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
| GB202015235D0 (en) | 2020-09-25 | 2020-11-11 | Ucl Business Plc | Anti-CD45 antibodies and related therapeutics |
| CN116601174A (zh) * | 2020-10-12 | 2023-08-15 | 索伦托药业有限公司 | Cd19定向的嵌合抗原受体构建体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| KR102349677B1 (ko) * | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| AU2016285552B2 (en) * | 2015-06-29 | 2022-10-13 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| EP3877416A4 (en) * | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF |
-
2020
- 2020-01-07 WO PCT/US2020/012637 patent/WO2020146432A1/en not_active Ceased
- 2020-01-07 CN CN202080017259.0A patent/CN113490504A/zh active Pending
- 2020-01-07 CA CA3125751A patent/CA3125751A1/en active Pending
- 2020-01-07 JP JP2021539400A patent/JP2022518150A/ja active Pending
- 2020-01-07 EP EP20739127.7A patent/EP3908296A4/en active Pending
- 2020-01-07 AU AU2020206117A patent/AU2020206117A1/en active Pending
-
2021
- 2021-07-06 US US17/368,815 patent/US20220062339A1/en active Pending
-
2025
- 2025-04-03 JP JP2025061674A patent/JP2025111482A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518150A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2020103301A5 (enExample) | ||
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2021534802A5 (enExample) | ||
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| RU2487877C2 (ru) | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) | |
| ES2719495T5 (en) | Anti-b7-h6 antibody, fusion proteins, and methods of using the same | |
| JP2022515318A5 (enExample) | ||
| JP2021524278A5 (enExample) | ||
| JP2020127426A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| JP2018523471A (ja) | システイン置換免疫グロブリン | |
| JP2020531043A5 (enExample) | ||
| JP2023521920A (ja) | 抗体－薬物コンジュゲート | |
| WO2023206350A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2017186337A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| EP2970473A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| EP1470146A2 (en) | Antibodies against the muc18 antigen | |
| KR102949500B1 (ko) | 접합을 위한 폴리펩티드 복합체 및 이의 용도 | |
| JP2021520201A5 (enExample) | ||
| JP2019512207A5 (enExample) |